Formulations of ion channel modulators and methods of preparation and use of ion channel modulators
Patent Information
- Application Number
- HK42026125246
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-09-24
- Filing Date
- 2026-06-24
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
(19) *EP004671248A3* (11) EP 4 671 248 A3 (12) EUROPEAN PATENT APPLICATION (88) Date of publication A3: 01.04.2026 Bulletin 2026 / 14 (43) Date of publication A2: 31.12.2025 Bulletin 2026 / 01 (21) Application number: 25204158.7 (22) Date of filing: 25.11.2020 (51) International Patent Classification (IPC): A61K 31 / 438 (2006.01) A61P 25 / 00 (2006.01) C07D 491 / 107 (2006.01) A61K 31 / 4985 (2006.01) C07D 487 / 04 (2006.01) (52) Cooperative Patent Classification (CPC): C07D 487 / 04; A61K 31 / 4985; A61P 25 / 00 (84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (30) Priority: 27.11.2019 US 201962941322 P 27.11.2019 US 201962941319 P 30.03.2020 US 202063001801 P 30.03.2020 US 202063001906 P 21.05.2020 US 202063028229 P 24.09.2020 US 202063082857 P 24.09.2020 US 202063082864 P (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: 20893872.0 / 4 065 114 (71) Applicant: Praxis Precision Medicines, Inc. Boston, MA 02110 (US) (72) Inventors: • MARTINEZ BOTELLA, Gabriel WAYLAND, MA 01778 (US) • LUNSMANN, Walter J HARVARD, MA 01451 (US) • GARAD, Sapna Makhija MALDEN, MA 02148 (US) • REED, David PELHAM, NH 03076 (US) • GRIFFIN, Andrew Mark QUEBEC, H9C2Y (CA) • KAHLIG, Michael Kristopher Mathieu REDWOOD CITY, CA 94062 (US) • MARRON, Brian Edward ADA, MI 49301 (US) • LOYA, Carlos Cambridge, MA 02138 (US) (74) Representative: J A Kemp LLP 80 Turnmill Street London EC1M 5QU (GB) (54) FORMULATIONS OF ION CHANNEL MODULATORS AND METHODS OF PREPARATION AND USE OF ION CHANNEL MODULATORS (57) The present invention is directed to, in part, compositions or dosage forms comprising fused hetero- aryl compounds useful for preventing and / or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnor- mal late / persistent sodium current.EP 4 67 1 24 8 A 3 Processed by Luminess, 75001 PARIS (FR) 2 EP 4 671 248 A3 5 10 15 20 25 30 35 40 45 50 55 3 EP 4 671 248 A3 5 10 15 20 25 30 35 40 45 50 55 4 EP 4 671 248 A3 5 10 15 20 25 30 35 40 45 50 55 Abstract This invention relates in part to compositions or dosage forms comprising fused heteroaryl compounds that can be used for the prevention and / or treatment of diseases or conditions associated with abnormal function of voltage-gated sodium ion channels (e.g., abnormal late sodium current / sustained sodium current). Methods for treating diseases or conditions associated with abnormal function of sodium ion channels are also provided herein, including neurological disorders (e.g., Dravier syndrome, epilepsy), pain, neuromuscular disorders, trigeminal autonomic headache (TAC), migraine, cranial neuropathy or multiple cranial neuropathy, and cortical diffusion inhibition (CSD). In another aspect, the invention provides methods for preparing ion channel modulators.
Claims
1. A suspension for oral administration, said suspension comprising Compound 1 represented by the following structural formula: or a pharmaceutically acceptable salt thereof, wherein Compound 1 is present in the suspension at a concentration of about 0.1 mg / mL to about 25 mg / mL.
2. The suspension of claim 1, wherein Compound 1 is present in the suspension at a concentration of about 0.1 mg / mL to about 10 mg / mL.
3. The suspension of claim 2, wherein Compound 1 is present in the suspension at a concentration of about 10 mg / mL.
4. The suspension of any one of claims 1-3, further comprising a filler and an emulsifier.
5. The suspension of claim 4, wherein the filler is selected from the group consisting of ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, caboxymethylcellulose, sodium hydroxypropylmethylcellulose, methylcellulose, methylethylcellulose, sodium carboxymethylcellulose, silicon dioxide, cetostearyl alcohol, cetyl alcohol, stearyl alcohol, Gelucire 33 / 01, Gelucire 39 / 01, Gelucire 43 / 01, glyceryl behenate, glyceryl palmitostearate, Softisan 100, Softisan 142, Softisan 378, Softisan 649, stearyl alcohol carbomer, xanthan gum, maltodextrin, acacia, tragacanth, povidone, and polyvinyl alcohol.
6. The suspension of claim 5, wherein the filler comprises (a) xanthan gum; or (b) povidone; or (c) silicon dioxide; or (d) methylcellulose.
7. The suspension of any one of claims 4-6, wherein the filler is present in the suspension at the concentration of about 0.1% to about 5% by weight.
8. The suspension of any one of claims 4-7, wherein the emulsifier is selected from the group consisting of polyoxyethylene sorbate, sorbitan long chain carboxylic acid esters, ethylene or propylene oxide block copolymers, a polyglycolyzed glyceride, sorbitan esters of oleate, a long chain carboxylic acid, polyethylene-polypropylene glycol block copolymers, sorbitan or sucrose long chain carboxylic acid esters, monoglycerides, diglycerides, and PEG derivatives of caprylic / capric triglycerides.
9. The suspension of claim 8, wherein the emulsifier is polyethylene-polypropylene glycol block copolymers, preferably wherein the polyethylene-polypropylene glycol block copolymers comprise Poloxamer 188.
10. The suspension of any one of claims 4-9, wherein the emulsifier is present in the suspension at a concentration of about 0.1% to about 3%.
11. The suspension of any one of claims 1-10, further comprising a lubricating agent, a preserving agent, a sweetening agent and a flavoring agent.
12. The suspension of claim 11, wherein the lubricating agent is selected from the group consisting of talc, magnesium stearate and mineral oil.
13. The suspension of claim 12, wherein the preserving agent is a methyl benzoate or a propylhydroxy benzoate.
14. The suspension of any one of claims 1-13, further comprising a buffer substance.
15. The suspension of claim 14, wherein the buffer substance comprises a phosphate.
